Tango Therapeutics (TNGX) AI Stock Analysis

• Market Cap: $833.90M
• Dividend Yield: N/A
• Average Volume (3M): 3.72M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.37
• Revenue Growth: -42.84%
• EPS Growth: -17.32%
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.35
• Shares Outstanding: 111,260,250
• 10 Day Avg. Volume: 5,619,394
• 30 Day Avg. Volume: 3,720,042
• PEG Ratio: -0.25
• Price to Book (P/B): 1.69
• Price to Sales (P/S): 8.02
• P/FCF Ratio: -2.55
• Enterprise Value/Market Cap: 0.50
• Enterprise Value/Revenue: 17.28
• Enterprise Value/Gross Profit: 17.73
• Enterprise Value/Ebitda: -2.75
• 1Y Price Target: $11.80
• Price Target Upside: 57.33% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 44 Neutral
• Price Target: $7.50 ▲(0.00% Upside)

Tango Therapeutics' overall stock score is primarily impacted by its financial performance, which is challenged by declining revenues and persistent losses. Technical analysis provides a mixed outlook with some positive momentum indicators, but valuation remains unattractive due to negative earnings and lack of dividends. The absence of earnings call insights and corporate events limits additional context.

Positive Factors

FDA Orphan Designation

Receiving FDA orphan designation can accelerate development and approval processes, providing market exclusivity and potential tax credits, enhancing long-term growth prospects.

Positive Clinical Trial Data

Successful clinical trial results bolster Tango's drug pipeline credibility, potentially leading to new partnerships and revenue streams, strengthening its market position.

Strong Partnerships

Strategic partnerships provide financial stability and access to resources, enhancing Tango's ability to innovate and bring new therapies to market, supporting long-term growth.

Negative Factors

Declining Revenue

Persistent revenue decline indicates challenges in maintaining sales momentum, which could hinder long-term financial stability and growth if not addressed.

Negative Cash Flow

Negative cash flow highlights operational inefficiencies and could limit Tango's ability to fund R&D and other strategic initiatives, impacting future growth.

Persistent Losses

Ongoing losses suggest operational challenges and may require cost restructuring or increased revenue generation to achieve sustainable profitability.

Tango Therapeutics Business Overview & Revenue Model

Company Description

Tango Therapeutics (TNGX) is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company specializes in precision medicine, leveraging its proprietary technology platform to discover and develop novel therapeutics that target specific genetic vulnerabilities in tumors. Tango Therapeutics operates primarily in the healthcare and pharmaceutical sectors, with a core focus on drug discovery and development aimed at improving patient outcomes in oncology.

How the Company Makes Money

Tango Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies, which may involve licensing agreements for its proprietary drug candidates. Additionally, the company may receive milestone payments as its products progress through various stages of development and regulatory approval. Revenue may also come from grants and funding from research institutions or government bodies aimed at supporting its research initiatives. The company’s ability to monetize its intellectual property and the success of its therapeutic candidates in clinical trials are significant factors contributing to its earnings.

Tango Therapeutics Financial Statement Overview

Summary

Tango Therapeutics faces significant financial challenges, with declining revenues and persistent losses impacting profitability. The balance sheet shows low leverage, which is a positive, but the negative return on equity and cash flow issues highlight operational inefficiencies. The company needs to focus on improving revenue growth and cash flow management to enhance financial stability.

Income Statement

Tango Therapeutics shows a declining revenue trend with a significant drop in the TTM period. The gross profit margin remains high, indicating efficient cost management, but the company struggles with profitability as evidenced by negative net profit and EBIT margins. The revenue growth rate is negative, reflecting challenges in maintaining sales momentum.

Balance Sheet

The company maintains a low debt-to-equity ratio, suggesting conservative leverage. However, the return on equity is negative, indicating that the company is not generating profits from shareholders' equity. The equity ratio is stable, but the overall financial health is impacted by consistent losses.

Cash Flow

Operating and free cash flows are negative, reflecting cash burn typical in biotechnology firms. The free cash flow growth rate shows slight improvement, but the operating cash flow to net income ratio indicates inefficiencies in converting income into cash. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	24.30M	42.07M	36.53M	24.86M	37.04M	7.66M
Gross Profit	23.67M	42.07M	-78.67M	20.83M	35.08M	6.03M
EBITDA	-152.65M	-143.10M	-111.76M	-109.46M	-57.29M	-51.48M
Net Income	-145.57M	-130.30M	-101.74M	-108.18M	-58.23M	-51.86M
Balance Sheet
Total Assets	237.89M	316.49M	402.57M	436.47M	500.15M	207.25M
Cash, Cash Equivalents and Short-Term Investments	181.21M	257.92M	336.88M	366.13M	485.25M	190.32M
Total Debt	35.01M	36.49M	38.92M	41.13M	1.50M	7.88M
Total Liabilities	102.94M	116.97M	149.46M	186.99M	155.41M	168.65M
Stockholders Equity	134.95M	199.52M	253.11M	249.48M	344.75M	38.60M
Cash Flow
Free Cash Flow	-149.17M	-132.25M	-119.51M	-116.77M	-61.36M	68.97M
Operating Cash Flow	-148.25M	-131.50M	-117.98M	-109.08M	-59.53M	70.07M
Investing Cash Flow	132.00M	86.13M	41.43M	26.40M	-183.43M	-145.47M
Financing Cash Flow	3.95M	47.66M	82.41M	1.61M	357.32M	80.88M

Tango Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.50
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Negative. The current price of 7.5 is below the 20-day moving average (MA) of 8.16, below the 50-day MA of 7.51, and above the 200-day MA of 4.34, indicating a neutral trend. The MACD of 0.24 indicates Positive momentum. The RSI at 44.35 is Neutral, neither overbought nor oversold. The STOCH value of 38.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TNGX.

Tango Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UPB	56 Neutral	$1.13B	―	―	―	―	―
IMTX	55 Neutral	$1.24B	―	-17.34%	―	83.36%	22.27%
SPRY	53 Neutral	$900.31M	―	-23.56%	―	22367.80%	-5.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNGX	44 Neutral	$833.90M	―	-76.09%	―	-42.84%	-17.32%
PRME	43 Neutral	$949.78M	―	-154.81%	―	739.42%	24.90%
ORKA	41 Neutral	$1.32B	-7.49	-53.15%	―	―	39.03%

Tango Therapeutics Corporate Events

Tango Therapeutics Announces Major Stock Offering

On October 23, 2025, Tango Therapeutics announced a registered direct offering of 21,023,337 shares of common stock and pre-funded warrants to purchase an additional 3,226,458 shares, expected to raise approximately $197 million. The proceeds will be used to advance the company’s pipeline and support general corporate purposes, with the offering anticipated to close on October 24, 2025. Additionally, Tango entered into a private placement agreement with an accredited investor for 1,732,101 shares, expected to generate $15 million. These financial moves are intended to fund operations and capital expenditures into 2028, strengthening Tango’s position in the biotechnology industry.

The most recent analyst rating on (TNGX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.

Tango Therapeutics Announces Preliminary Financial Results

On October 23, 2025, Tango Therapeutics announced preliminary unaudited financial results, estimating $152.8 million in cash and marketable securities as of September 30, 2025. The company also provided a clinical update on its ongoing Phase 1/2 trial of vopimetostat, highlighting its potential as a best-in-class treatment for MTAP-deleted solid tumors, with plans for a pivotal study in second-line pancreatic cancer to begin in 2026.

The most recent analyst rating on (TNGX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.

Tango Therapeutics’ Chief Legal Officer Resigns

On August 21, 2025, Douglas Barry announced his resignation as Chief Legal and Compliance Officer and Corporate Secretary of Tango Therapeutics, effective September 12, 2025, to pursue another opportunity. This change in leadership may impact Tango Therapeutics’ operations and strategic direction as they adjust to the departure of a key executive.

The most recent analyst rating on (TNGX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.

Tango Therapeutics Reports Q2 2025 Financial Results

Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision cancer medicines through the genetic principle of synthetic lethality. The company recently reported its financial results for the second quarter of 2025, highlighting significant progress in its clinical trials and strategic collaborations.